Campbell Research Institute scientists, in collaboration with scientists at University of Queensland, have discovered a compound that protected the organisms that live in the vascular system of the mouse heart.
The study, through the University of Queensland Centre for Regenerative Medicine, found that the compound, named starchotefracin, protected the FGR4 cells that line the blood vessels in the heart.
“Our next step is to put this compound to work with state-of-the-art human gene editing tools to create even more effective replicas of the human gene that encodes the FGR4 cell receptor and protects this magical innate immunity for life, ” said Associate Professor Rasa Edistain at Campbell, who co-authored a paper describing the research in Nature Communications.
A key challenge in gene editing technology is the elimination of unwanted gene-mutating genes from the human genome.
“We are working to eliminate all the deletion of capable genes from the human genome except the ones that condition the heart cells, like in patients with heart failure, ” he said.
Amid the mix of gene editing tools now being used, there is a critical challenge in finding a drug that performs effectively in the human liver against infections.
In order to address this issue, researchers built complex delivery systems which include gene editing proteins and small molecules that promote the efficient further generation of human FGR4 cells.
“It’s like going from wanting to have a baby to wanting to survive the next 10 years by smoking a pack. You need a strong background and then you need to understand where you are, how to keep it alive and develop the guts to kill the infection, ” Associate Professor Edistain said.
MAC-AS-CLX was tested in the heart and liver of rats after it was treated for 10 days in a protective added period, allowing our previously established and effective compounds to circulate in the body.